Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin
This article was originally published in The Pink Sheet Daily
Executive Summary
Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.